Evidence map›Paper›PMID 40410522›Full record

ArticleDiscover oncology2025

Integrative machine learning model for subtype identification and prognostic prediction in lung squamous cell carcinoma.

Guangliang Duan, Qi Huo, Wei Ni, Fei Ding, Yuefang Ye, Tingting Tang, Huiping Dai

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guangliang DuanDepartment of Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China.
Qi HuoDepartment of Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China.
Wei NiDepartment of Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China.
Fei DingDepartment of Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China.
Yuefang YeDepartment of Gastroenterology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China.
Tingting TangDepartment of Hematology and Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China.
Huiping DaiDepartment of Proctology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310015, Zhejiang, People's Republic of China. dhp20221316@hznu.edu.cn.

Funding

Natural Science Foundation of Anhui Province 2208085MH247Zhejiang provincial Health Department Project 2022KY971Zhejiang provincial nature Foundation Fund Project LY16H030017
6 · The paper itself

Abstract

backgroundLung squamous cell carcinoma (LUSC) is a leading cause of cancer-related mortality, and tumor heterogeneity could result in diverse prognostic subtypes. Traditional prognostic factors, like tumor, node, and metastasis (TNM) staging, offer limited predictive accuracy. This study aims to identify LUSC subtypes and develop predictive models that have the potential to improve prognosis prediction accuracy and support personalized treatment.

methodsExpression and clinical data were collected from three datasets. One dataset (TCGA-LUSC) was used as a training set, while the others (GSE30219 and GSE73403) were independent testing sets. Unsupervised clustering was applied to the training set to identify LUSC subtypes. The relationship between survival outcomes and these identified subtypes was validated in the testing sets using binary machine learning models and survival curve analysis. The impact of chemotherapy on the prognosis for subtypes was also presented. Subsequently, four survival machine learning models were developed to predict LUSC prognosis. These models were validated in the testing sets and integrated into an online tool to assist in survival prediction.

resultsTwo subtypes, C1 and C2, were identified in the training set. The C1 subtype was associated with poorer survival outcomes and was enriched in cancer-associated fibroblasts and macrophages. In contrast, the C2 subtype correlated with better outcomes and was enriched in CD8 + T cells. Regarding chemotherapy, the C2 subtype with chemotherapy showed the best survival outcomes compared to other groups. A 9-gene signature was derived from the model's importance values for subtype prediction and included TGM2, AOC3, TBXA2R, RGS3, DLC1, MMP19, ACVRL1, TCF21, and TIMP3. This signature outperformed 14 published signatures and clinical variables at survival prediction with the highest time-dependent AUC (tdAUC) and concordance index (C-index). Four machine learning models were developed using this signature, achieving tdAUC values of 0.712 and 0.684 and C-index values of 0.682 and 0.625 in the independent testing sets. An online tool for predicting survival probabilities for LUSC patients up to 10 years post-treatment is available at https://hznuduan.shinyapps.io/LCSP/ .

conclusionWe identified two LUSC subtypes by unsupervised clustering and developed an online tool for prognosis prediction using supervised machine learning models.

Indexed as

ChemotherapyLung squamous cell carcinomaMachine learningSurvival predictionUnsupervised clustering

Identifiers

PMID40410522
PMCPMC12102021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.